Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. evolve

EVOLVE SIGNED

Extracellular Vesicle-Internalizing Receptors (EVIRs) for Cancer ImmunoGeneTherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 EVOLVE project word cloud

Explore the words cloud of the EVOLVE project. It provides you a very rough idea of what is the project "EVOLVE" about.

ancillary    extracellular    innovative    leverage    pathogens    inactivated    microenvironment    preclinical    outside    vesicles    apcs    trials    exposed    broadening    clones    presenting    whereby    vaccination    stimulating    evirs    shortcomings    previously    immunotherapy    primarily    engineering    patients    inoculation    conditioning    apc    gene    propel    deployment    designed    combination    delivered    antigen    presentation    cell    transfer    prospectively    dramatic    mouse    durable    cancer    cellmediated    models    platform    witnessing    strategies    overcomes    evolve    therapeutic    cells    hence    treatments    technologies    efficient    transformative    cross    modality    envisions    vaccines    evs    regressions    clinical    interventions    box    optimize    antigens    hurdles    immune    puts    largely    strategy    immunotherapies    administration    breast    unsatisfactory    combined    human    barriers    receptors    elicit    abating    reactive    melanoma    eradication    tumor    chimeric    immunity    ev    highlighting    anti   

Project "EVOLVE" data sheet

The following table provides information about the project.

Coordinator		 ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Total cost 1˙958˙919 €
 EC max contribution 1˙958˙919 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-COG
 Funding Scheme ERC-COG
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 1˙958˙919.00

Map

 Project objective

We are witnessing transformative results in the clinical application of both cancer immunotherapies and gene transfer technologies. Tumor vaccines are a specific modality of cancer immunotherapy. Similar to vaccination against pathogens, tumor vaccines are designed to elicit a specific immune response against cancer. They are based on the administration of inactivated cancer cells or tumor antigens, or the inoculation of antigen-presenting cells (APCs) previously exposed to tumor antigens. In spite of significant development and testing, tumor vaccines have largely delivered unsatisfactory clinical results. Indeed, while some patients show dramatic and durable cancer regressions, many do not respond, highlighting both the potential and the shortcomings of current vaccination strategies. Hence, identifying and abating the barriers to effective cancer vaccines is key to broadening their therapeutic reach. The goal of EVOLVE (EVirs to Optimize and Leverage Vaccines for cancer Eradication) is to propel the development of effective APC-based tumor vaccines using an innovative strategy that overcomes several key hurdles associated with available treatments. EVOLVE puts forward a novel APC engineering platform whereby chimeric receptors are used to both enable the specific and efficient uptake of cancer-derived extracellular vesicles (EVs) into APCs, and to promote the cross-presentation of EV-associated tumor antigens for stimulating anti-tumor immunity. EVOLVE also envisions a combination of ancillary ‘outside of the box’ interventions, primarily based on further APC engineering combined with innovative pre-conditioning of the tumor microenvironment, to facilitate the deployment of effective APC-driven, T-cellmediated anti-tumor immunity. Further to preclinical trials in mouse models of breast cancer and melanoma, our APC platform will be used to prospectively identify novel human melanoma antigens and reactive T cell clones for broader immunotherapy applications.

 Publications

year authors and title journal last update
List of publications.
2019 Chiara Cianciaruso, Tim Beltraminelli, Florent Duval, Sina Nassiri, Romain Hamelin, André Mozes, Hector Gallart-Ayala, Gerardo Ceada Torres, Bruno Torchia, Carola H. Ries, Julijana Ivanisevic, Michele De Palma
Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles
published pages: 3062-3080.e11, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.05.008 		Cell Reports 27/10 2020-01-29
2019 Caleb R. Perez, Michele De Palma
Engineering dendritic cell vaccines to improve cancer immunotherapy
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-13368-y 		Nature Communications 10/1 2020-01-29
2018 Mario Leonardo Squadrito, Chiara Cianciaruso, Sarah K Hansen, Michele De Palma
EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens
published pages: 183-186, ISSN: 1548-7091, DOI: 10.1038/nmeth.4579 		Nature Methods 15/3 2019-03-11
2019 Ioanna Keklikoglou, Chiara Cianciaruso, Esra Güç, Mario Leonardo Squadrito, Laura M. Spring, Simon Tazzyman, Lore Lambein, Amanda Poissonnier, Gino B. Ferraro, Caroline Baer, Antonino Cassará, Alan Guichard, M. Luisa Iruela-Arispe, Claire E. Lewis, Lisa M. Coussens, Aditya Bardia, Rakesh K. Jain, Jeffrey W. Pollard, Michele De Palma
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
published pages: 190-202, ISSN: 1465-7392, DOI: 10.1038/s41556-018-0256-3 		Nature Cell Biology 21/2 2019-03-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVOLVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVOLVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More